Sleep Quality and Levodopa Intestinal Gel Infusion in Parkinson’s Disease: A Pilot Study

Table 1

Changes in “off” time hours, UPDRS values, cognitive function, body mass index, and pharmacological therapy at baseline and after 6 months of LCIG infusion.

Variables	Baseline	Follow-up	value
Off time hours recorded in Parkinson’s disease diary© (daily mean “off” time)	6.3 ± 1.4	1.1 ± 0.7	<0.001
UPDRS part IV (dyskinesia)	5.4 ± 2.4	2.9 ± 1.1	0.028
UPDRS part II (activities of daily living)
On	11.4 ± 5.9	10.9 ± 5.6	0.742
Off	22.9 ± 8.3	22.3 ± 7.5	0.231
UPDRS part III (motor examination)
On	18 ± 3.7	16.6 ± 4.9	0.245
Off	34.1 ± 11.1	34.1 ± 11.1	—
UPDRS part I (mentation, behavior, and mood)	3.6 ± 3.7	2.4 ± 2.1	0.156
MMSE (cognitive function)	29 (27–30)	29 (27–30)	0.317
Body mass index (BMI)	24.5 ± 4.0	23.8 ± 3.3	0.424
Bedtime drugs, no. patients
Benzodiazepine drugs	6/7	6/7	1.000
Serotonin selective reuptake inhibitor	4/7	4/7	1.000
Neuroleptic drugs	1/7	2/7	1.000

Data as mean ± standard deviation unless otherwise stated.